Program
EYU688
A development code.
In Novartis's pipeline, NS4B inhibitor
. Its studies are mostly in Dengue, led by Novartis.
Furthest: phase 2, since Aug 17, 20231 company-led study, 1 open or runningNext primary completion: Jul 22, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 2since Aug 17, 2023 | Aug 17, 2023 | Jul 22, 2027phase 2 · NCT06006559 |
- Named in Novartis’s own pipeline as
EYU688
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2023First study: phase 2 study in DengueFirst studyNCT06006559 · 108 planned · Brazil, Colombia, India and more
Ahead
- Jul 22, 2027Primary completion: phase 2 study in DengueNCT06006559
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“NS4B inhibitor”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06006559Dengue · Brazil, Colombia, India and more | 2 | Recruiting | Jul 22, 2027 | 108 |
How it is read
Names in the registry
- “EYU688”, 1 entry
Codes read as this program: EYU688.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.